Fiche publication
Date publication
février 2026
Journal
Neuro-oncology advances
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGER Antoine
Tous les auteurs :
Tolboom N, Verger A, Preusser M, Geurts M, Scheltens P, Albert NL
Lien Pubmed
Résumé
The evolution of amyloid PET in Alzheimer's disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET's trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.
Référence
Neurooncol Adv. 2026 02 16;8(1):vdag043
